Biblioteca Humberto Rosselli Quijano
Información del autor
Autor Takashi Futamura |
Documentos disponibles escritos por este autor (2)
Refinar búsqueda
Improvement of dizocilpine-induced social recognition deficits in mice by brexpiprazole, a novel serotonin–dopamine activity modulator / Noriko Yoshimi en European Neuropsychopharmacology, Año 2015 - Vol. 25 - No.3 (Marzo)
[artículo]
Título : Improvement of dizocilpine-induced social recognition deficits in mice by brexpiprazole, a novel serotonin–dopamine activity modulator Tipo de documento: texto impreso Autores: Noriko Yoshimi, Autor ; Takashi Futamura, Autor ; Kenji Hashimoto, Autor Fecha de publicación: 2021 Artículo en la página: pp. 356-364 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Fármaco antipsicótico, Brexpiprazol, Dizocilpina, Reconocimiento social, Receptor 5-HT1A Resumen: Cognitive impairment, including impaired social cognition, is largely responsible for the deterioration in social life suffered by patients with psychiatric disorders, such as schizophrenia and major depressive disorder (MDD). Link: ./index.php?lvl=notice_display&id=26816
in European Neuropsychopharmacology > Año 2015 - Vol. 25 - No.3 (Marzo) . - pp. 356-364[artículo] Improvement of dizocilpine-induced social recognition deficits in mice by brexpiprazole, a novel serotonin–dopamine activity modulator [texto impreso] / Noriko Yoshimi, Autor ; Takashi Futamura, Autor ; Kenji Hashimoto, Autor . - 2021 . - pp. 356-364.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in European Neuropsychopharmacology > Año 2015 - Vol. 25 - No.3 (Marzo) . - pp. 356-364
Palabras clave: Fármaco antipsicótico, Brexpiprazol, Dizocilpina, Reconocimiento social, Receptor 5-HT1A Resumen: Cognitive impairment, including impaired social cognition, is largely responsible for the deterioration in social life suffered by patients with psychiatric disorders, such as schizophrenia and major depressive disorder (MDD). Link: ./index.php?lvl=notice_display&id=26816 Potentiation of neurite outgrowth by brexpiprazole, a novel serotonin–dopamine activity modulator / Tamaki Ishima en European Neuropsychopharmacology, Año 2015 - Vol. 25 - No.4 (Abril)
[artículo]
Título : Potentiation of neurite outgrowth by brexpiprazole, a novel serotonin–dopamine activity modulator : A role for serotonin 5-HT1A and 5-HT2A receptors Tipo de documento: texto impreso Autores: Tamaki Ishima, Autor ; Takashi Futamura, Autor ; Yuta Ohgi, Autor Fecha de publicación: 2021 Artículo en la página: pp. 505-511 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Brexpiprazol, Crecimiento de neuritas, Señalización Ca2 +, Receptores IP3, Receptor 5-HT1A, Receptor 5-HT2A Resumen: Brexpiprazole, a novel atypical antipsychotic drug, is currently being tested in clinical trials for treatment of psychiatric disorders, such as schizophrenia and major depressive disorder. Link: ./index.php?lvl=notice_display&id=26798
in European Neuropsychopharmacology > Año 2015 - Vol. 25 - No.4 (Abril) . - pp. 505-511[artículo] Potentiation of neurite outgrowth by brexpiprazole, a novel serotonin–dopamine activity modulator : A role for serotonin 5-HT1A and 5-HT2A receptors [texto impreso] / Tamaki Ishima, Autor ; Takashi Futamura, Autor ; Yuta Ohgi, Autor . - 2021 . - pp. 505-511.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in European Neuropsychopharmacology > Año 2015 - Vol. 25 - No.4 (Abril) . - pp. 505-511
Palabras clave: Brexpiprazol, Crecimiento de neuritas, Señalización Ca2 +, Receptores IP3, Receptor 5-HT1A, Receptor 5-HT2A Resumen: Brexpiprazole, a novel atypical antipsychotic drug, is currently being tested in clinical trials for treatment of psychiatric disorders, such as schizophrenia and major depressive disorder. Link: ./index.php?lvl=notice_display&id=26798